Oncology Central

Glioblastoma vaccine yields promising interim survival results in Phase III trial

0
Interim blinded survival data has been released from the Phase III clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma patients; early findings from the 11-year study involving more than 300 individuals worldwide demonstrates promising survival results.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.